2018 Consensus of the French Society of Endocrinology: endocrine toxicities of cancer immunotherapies - Archive ouverte HAL Access content directly
Journal Articles Correspondances en Métabolismes, Hormones, Diabètes et Nutrition Year : 2019

2018 Consensus of the French Society of Endocrinology: endocrine toxicities of cancer immunotherapies

Frederic Costinetti
  • Function : Author
Frederique Aibarel
  • Function : Author
Jerome Bertherat
  • Function : Author
Philippe Caron
  • Function : Author
Consensus Sfe 2018
  • Function : Author

Abstract

Immunotherapy induced side effects: Are frequent, usually well-tolerated, and can lead to thyroid, pituitary, and less frequently adrenals and pancreas (fulminant diabetes) disease,. Do not contra-indicate immunotherapy, and rarely require high dose glucocorticoids; Need to be screened for, as there are acute manifestations, and replacement treatments can be given lifelong; Require a pre-immunotherapy evaluation; Require a careful follow-up at least during the first 6 months of immunotherapy.
Not file

Dates and versions

hal-02461465 , version 1 (30-01-2020)

Identifiers

  • HAL Id : hal-02461465 , version 1

Cite

Frederic Costinetti, Francoise Borson-Chazot, Frederique Aibarel, Francoise Archambeaud, Jerome Bertherat, et al.. 2018 Consensus of the French Society of Endocrinology: endocrine toxicities of cancer immunotherapies. Correspondances en Métabolismes, Hormones, Diabètes et Nutrition, 2019, 23 (2), pp.31-36. ⟨hal-02461465⟩
98 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More